Iovance Biotherapeutics, Inc.

IOVABiotech

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

6 drugs in development

Phase 32

Phase 23

Phase 11

By Therapeutic Area

top 1

Oncology

6100%

R&D Momentum

37/100

Pipeline Velocity

6/100

Trial Completion Rate

60/100

Pipeline Concentration

100/100

Pipeline Freshness

68/100

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Available

Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

Earlier

Jun 27, 2026TrialA Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer

Jun 27, 2026TrialA Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma

Nov 28, 2025TrialA Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

Mar 11, 2025TrialA Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

Oct 29, 2024TrialA Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

Mar 28, 2024TrialStudy of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

Jul 20, 2022TrialA Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

4 more events

Feb 19, 2020TrialStudy of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

May 7, 2019TrialStudy of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Feb 28, 2018TrialStudy of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

Jun 22, 2017TrialStudy of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Therapeutic Focus

OncologyOtherInfectious DiseaseImmunologyNeurologyNephrologyHematologyCardiovascularMetabolic & EndocrinePsychiatry

Pipeline

Drug Pipeline

Oncology

LN-145Phase 2

AmtagviPhase 3

AmtagviPhase 2

LN-145Phase 2

AmtagviPhase 2

IOV-3001Phase 2

Metastatic Melanoma

AmtagviPhase 3

Pembrolizumab with Optional Crossover PeriodPhase 3

IOV-4001Phase 2

Metastatic Non Small Cell Lung Cancer

LN-145Phase 2

Non-Small Cell Lung Cancer

LN-145Phase 2

Squamous Cell Carcinoma

LN-145Phase 2

LN-145-S1Phase 2

Undifferentiated Pleomorphic Sarcoma

AmtagviPhase 1

Uveal Melanoma

AmtagviPhase 1

Regulatory

Regulatory Timeline

19921 event

FDAMay 5

Proleukin — PROLEUKIN

Application BLA103293 (BLA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)